Radius Health sees U.S. sales as high as $175M this year; shares up 3%

|About: Radius Health, Inc. (RDUS)|By:, SA News Editor

Radius Health (RDUS +3.2%) reports that its has surpassed 2018 guidance with TYMLOS (abaloparatide) generating more than $98M in sales. A 5.9% price hike went into effect on January 1.

Quick assets totaled more than $220M at year-end.

2019 outlook: TYMLOS sales of $155M - 175M (unchanged).

#JPM19

Subscribe for full text news in your inbox